Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

January 1, 2022

Study Completion Date

May 1, 2022

Conditions
COVID-19
Interventions
DIETARY_SUPPLEMENT

D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester

"The intervention is D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester and will be bought commercially. As an example: One bottle of KetoneAid KE4 PRO with 60 ml contains 30 g D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester. For more information please refer to: https://shop.ketoneaid.com/collections/all/products/ke4-pro. Placebo will be a taste-matched water solution provided by the company. The placebo solution and the active solution will be prepared in identic bottles and investigators will be blinded."

DIETARY_SUPPLEMENT

Placebo

Taste-matched water

Trial Locations (1)

2400

Bispebjerg Hospital, Copenhagen

All Listed Sponsors
lead

Steno Diabetes Center Copenhagen

OTHER

NCT04573764 - Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19 | Biotech Hunter | Biotech Hunter